MLH1 Antibodies

Santa Cruz Biotechnology features a diverse variety of MLH1 monoclonal antibodies for research focused on understanding MLH1's role in DNA mismatch repair and its implications in various cancers. MLH1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). MLH1 is a critical component of the DNA mismatch repair system, which helps maintain genomic stability by correcting errors that occur during DNA replication. Deficiencies in MLH1 function can lead to microsatellite instability and are associated with hereditary nonpolyposis colorectal cancer (Lynch syndrome). Understanding MLH1 expression and function is essential for elucidating its role in tumorigenesis and developing targeted therapies. MLH1 monoclonal antibodies enable researchers to investigate DNA repair mechanisms and molecular pathways involved in cancer development. Studying MLH1 can provide insights into potential therapeutic strategies for cancer treatment. Research with MLH1 monoclonal antibodies contributes to advancing our understanding of genomic stability and cancer biology. Santa Cruz Biotechnology MLH1 monoclonal antibodies support researchers worldwide in their pursuit of scientific discoveries that may lead to improved cancer treatments and diagnostic approaches.